4 Merger and Acquisitions Stock Stories for Midweek Due Diligence

Newcastle Investment Corp. (NYSE:NCT): Current price $5.77

On Wednesday, Newcastle said that it has purchased Dow Jones Local Media Group from News Corp at a price of $87 million. The firm made a total equity investment of $54 million, including transaction expenses, and financed the remainder of the price with $33 million of debt. Local Media Group operates 33 local publications, of which include 8 daily and 15 weekly newspapers in 7 states. Several of these publications have been supplying crucial local content to their communities for more than 75 years.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NCT 20130904

Herbalife Ltd. (NYSE:HLF): Current price $63.68

In a regulatory filing on Wednesday, Chief Executive William Stiritz, of the company that makes Raisin Bran, has taken a 5.2-percent position in Herbalife Ltd., giving the company more support as it resists accusations that it is a pyramid scheme. Stiritz, who is chairman and CEO of Post Holdings Inc., is now the fourth biggest Herbalife shareholder following the stock purchase.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HLF 20130904

Accelrys, Inc. (NASDAQ:ACCL): Current price $9.20

Accelrys said Wednesday that it has bought the Environmental Health & Safety compliance solutions provider ChemSW, Inc., furthering Accelrys’ scientific innovation lifecycle management strategy by supplying solutions for managing and tracking the source, use, and disposal of chemicals spanning the entire lab-to-plant value chain.

In consideration for purchasing all of the outstanding capital stock of ChemSW, Accelrys will pay to the ChemSW shareholders an aggregate amount of about $15.3 million in cash, subject to working capital and other adjustments. In addition, certain executives of ChemSW may be entitled to receive as much as $2 million, calculated upon achievement of certain operating milestones during the first two years, following the date of the transaction close. Accelrys provides scientific innovation lifecycle management software.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACCL 20130904

C.R. Bard, Inc. (NYSE:BCR): Current price $116.73

It was announced Wednesday that C.R. Bard will acquire Rochester Medical, Inc. which develops and supplies silicone urinary incontinence and urine drainage products at a purchase price of $20 per share, or roughly $262 million in total, to be paid at the closing, which should take place later in 2013.

This transaction is structured as a merger, has been cleared by each firm’s board, and is subject to the usual closing conditions, including approval of the shareholders of Rochester Medical and regulatory approvals. This acquisition makes a compelling strategic fit for Bard and greatly improves its position in a $930-million global urology homecare market.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BCR 20130904

Don’t Miss: Will a Refreshed Apple TV Also Hit the Stage Sept. 10?